PZ 01

Drug Profile

PZ 01

Alternative Names: Anti-CD19 CAR-T cell therapy - Pinze Lifetechnologies; PZ01

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pinze Lifetechnology
  • Developer Navy General Hospital; Pinze Lifetechnology
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Acute lymphoblastic leukaemia; B cell lymphoma

Most Recent Events

  • 20 Jul 2017 Clinical trials in Acute lymphoblastic leukaemia (In adolescents, In adults, Second-line therapy or greater) in China (IV) (ChiCTR-ONh-17012060)
  • 20 Jul 2017 Clinical trials in B-cell lymphoma (In adolescents, In adults, Second-line therapy or greater) in China (IV) (ChiCTR-ONh-17012060)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top